REGN Trading Analysis - 10/23/2026 12:31 PM — TRU-SENTIMENT

News Headlines & Context

Recent general-knowledge headlines and context for Regeneron Pharmaceuticals (REGN):

• REGN reported Q2 2026 earnings with EPS beating estimates, supported by continued Eylea franchise strength and Dupixent expansion.
• FDA accepted a supplemental Biologics License Application for a REGN immunotherapy candidate, with a PDUFA date expected in late 2026.
• Company announced a new share repurchase authorization amid strong free cash flow generation.
• Competitive pressure in ophthalmology from biosimilars remained a noted sector concern among analysts.
• Broad biotech rally in October 2026 lifted large-cap names, with REGN participating in the upward move.

Context: These fundamental and sector catalysts broadly align with the bullish options sentiment and recovery in price from September lows, though the embedded data shows an overbought RSI that tempers near-term enthusiasm.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data:

• Trailing P/E: 19.30; Trailing EPS: $41.88
• Market Cap: $84,373,166,825.00; Shares Outstanding: 102,955,000.00
• Dividend Yield: 0.47%; Dividend Rate: $3.76; Ex-Dividend Date: 2026-08-18
• Beta: 0.06 (very low market correlation)
• 52-Week High: $859.34; 52-Week Low: $572.75
• Institutional Ownership: 63.71%
• Average Volume: 692,000.00; Historical Volatility: 28.80%
• PEG Ratio, Forward P/E, Forward EPS, P/B, Revenue Growth, Margins, ROE, D/E, FCF, Analyst Target: All null/not provided

Revenue growth rate, profit margins, and ROE are not available in the data. The trailing P/E of 19.30 with EPS of $41.88 suggests a moderate valuation relative to typical pharma peers, but no PEG or sector comparison metrics are provided. Fundamental strengths include low beta (0.06) and majority institutional ownership (63.71%). Concerns are the lack of disclosed leverage, cash flow, and analyst consensus data. Fundamentals neither confirm nor contradict the technical recovery, as price sits below the 52-week high ($859.34) but well above the low ($572.75).

Current Market Position

Current price per indicators: $819.52. Recent daily history shows a close of $819.52 on 2026-10-22 after a high of $825.52 and low of $800.00, with volume of 622,331 (above 20-day avg of 461,050). Minute bars for 2026-10-22 15:55 show final close $819.33, with intraday range $818.89–$821.90 in the last 20 minutes, indicating late-session softness from $821.90 to $819.33.

Technical Analysis

Price is above all SMAs (5 > 20 < 50 but price > all), showing bullish alignment. RSI at 80.60 indicates overbought. MACD (7.24) above signal (5.79) with positive histogram (1.45) is bullish. Bollinger upper is $820.51; price $819.52 is at the band edge (expansion). 30-day range: price near top (high $825.52).

True Sentiment Analysis (Delta 40-60 Options)

Options flow sentiment: Bullish

Call Dollar Volume: $138,910.00 (94.50%) Put Dollar Volume: $8,140.00 (5.50%) Total: $147,050.00

Call contracts 42 vs put 3; call trades 10 vs put 2. Pure directional conviction is heavily call-sided (94.5%). This suggests near-term upside expectations. Divergence: option_spreads JSON notes "Divergence detected between technical indicators and options sentiment" with advice to wait for alignment, citing bullish sentiment but no clear technical direction (though embedded technicals show overbought bullishness).

Key Price Levels (Observational Only)